<DOC>
	<DOC>NCT02571257</DOC>
	<brief_summary>The purpose of this study is to evaluate the effect of gemcabene on LDL-C and other lipid parameters in hypercholesterolemic patients on a stable dose of a statin.</brief_summary>
	<brief_title>Efficacy and Safety of Gemcabene in Hypercholesterolemic Patients on Stable Statin Therapy</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
	<criteria>Males and Females 18 to 65 years of age Baseline LDLC ≥ 130 mg/dL (3.4 mmol/L) If female, postmenopausal or surgically menopausal Triglycerides (TG) &gt;400 mg/dL Creatine phosphokinase (CPK) &gt;3 × the upper limit of normal (ULN) Body Mass Index (BMI) &gt;35 kg/m2 Uncontrolled diabetes mellitus (HbA1c &gt;10%) Renal dysfunction (blood urea nitrogen [BUN] or creatinine &gt;2 × ULN) Hepatic dysfunction (aspartate aminotransferase [AST] or alanine aminotransferase [ALT] &gt;2 × ULN) Myocardial infarction, severe or unstable angina pectoris, coronary angioplasty, coronary artery bypass graft, or any other major cardiovascular event resulting in hospitalization in previous month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>LDL-C</keyword>
	<keyword>Lipid Regulator</keyword>
</DOC>